Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT-04: sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in first-line PD-L1-positive metastatic triple-negative breast cancer
MOH_2022-10-18_012088Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Sacituzumab govitecan + pembrolizumab with Physician's choice chemotherapy + pembrolizumab (2 arms). Started Oct 2022; status: active, not recruiting.
02
Drugs
sacituzumab govitecanpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on MOH_2022-10-18_012088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-10-18_012088.